ACR Image Metrix Completes Successful Second Year as Imaging CRO
Philadelphia, PA - September 22, 2009
“The value of imaging in clinical trials is evident and is paving the way for better integration of molecular, functional and volumetric imaging in the drug discovery process," said Mike Morales, ACR Image Metrix general manager.
“This year we also expanded our office space and core imaging laboratories, allowing us greater capacity to handle larger global research projects,” said Veronique Cardon, ACR Image Metrix director of business development.
The 10,000 square-foot facility also includes two learning laboratories designed for researchers to acquire the knowledge and skills needed to perform advanced imaging techniques. The core imaging laboratory has evolved to include a focus on the increasing challenges associated with advanced imaging capabilities in imaging clinical research today. These advanced imaging techniques include DCE-MRI, diffusion weighted/tensor imaging, FDG and FLT-PET and many more. In addition, ACR Image Metrix also offers services to the medical device industry in conducting clinical research to secure regulatory approvals for their new devices and software products such as CAD (computer aided detection).
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025